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Objective: Persons with depressive symptoms generally have higher rates of medication 
nonadherence than persons without depressive symptoms. However, little is known about 
whether this association differs by comorbid medical condition or whether reasons for nonad-
herence differ by depressive symptoms or comorbid medical condition.
Methods: Self-reported extent of nonadherence, reasons for nonadherence, and depressive 
symptoms among 1,026 veterans prescribed medications for hypertension, dyslipidemia, and/
or type 2 diabetes were assessed.
Results: In multivariable logistic regression adjusted for clinical and demographic factors, the 
odds of nonadherence were higher among participants with high depressive symptom burden for 
dyslipidemia (n=848; odds ratio [OR]: 1.42, P=0.03) but not hypertension (n=916; OR: 1.24, 
P=0.15), or type 2 diabetes (n=447; OR: 1.15, P=0.51). Among participants reporting nonadher-
ence to antihypertensive and antilipemic medications, those with greater depressive symptom 
burden had greater odds of endorsing medication nonadherence reasons related to negative 
expectations and excessive economic burden. Neither extent of nonadherence nor reasons for 
nonadherence differed by depressive symptom burden among patients with diabetes.
Conclusion: These findings suggest that clinicians may consider tailoring interventions to 
improve adherence to antihypertensive and antilipemic medications to specific medication 
concerns of participants with depressive symptoms.
Keywords: adherence, compliance, chronic conditions, depression, heterogeneity
Introduction
Pharmacotherapy for hypertension, dyslipidemia, and type 2 diabetes can reduce 
the risk of major cardiovascular and cerebrovascular events, but adherence is often 
suboptimal.1–3 Medication nonadherence across these cardiometabolic conditions is 
associated with adverse events, greater inpatient and outpatient health care utilization, 
and higher health care costs.4,5
In patients with these conditions, numerous studies have shown that coexisting 
depressive symptoms are associated with higher rates of medication nonadherence.6–19 
However, it is unclear whether these medication nonadherence rates differ across these 
three comorbid conditions. Although prior condition-specific studies examining the 
role of depression in nonadherence have indicated different rates of nonadherence,1,20,21 
these studies have used different measures of nonadherence in different populations 
at different times. To our knowledge, no studies have specifically examined the asso-
ciation between depressive symptoms and medication nonadherence in concordant 
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conditions using a consistent measure in the same population 
at the same time.22
Medication nonadherence may differ by depressive symp-
tom burden because depressed patients tend to have a fore-
shortened view of the future23–26 and may be more sensitive to 
physical discomfort. Medications for these three conditions 
differ in their regimen complexity, side effects, out-of-pocket 
costs, and early consequences of nonadherence. For example, 
nonadherence to diabetes medications may be driven by 
regimen complexity (particularly if insulin is required) or its 
considerable side effects for some patients, despite the short 
(primarily insulin) and early adverse effects of nonadherence. 
Nonadherence to antihypertensive medications may also be 
driven by its sometimes complex regimen or inconvenient 
side effects. The impact of depressive symptoms on nonad-
herence to lipid-lowering medications may be more modest 
because these medications have the least complex regimen 
(a single statin), the fewest side effects, and typically the 
lowest out-of-pocket costs.
Using a validated self-report measure that distin-
guishes extent of medication nonadherence from reasons 
for nonadherence,27 we compared nonadherence rates and 
the reasons for reported nonadherence among participants 
with low and high depressive symptom burdens who were 
prescribed medication for at least one of three cardiometa-
bolic conditions (hypertension, dyslipidemia, or diabetes). 
Based on prior literature, we expected that the association 
between depressive symptoms and extent of nonadherence 
would differ between patients with these different condi-
tions for the reasons noted above. To inform what underlies 
the extent of nonadherence reported, we also examined the 
association between depressive symptoms and reasons for 
nonadherence among the subset of patients reporting non-
adherence. These findings can serve to guide interventions 
to improve adherence using a framework sensitive to the 
unique barriers presented by different patients, medications, 
and disease types.
Methods
study setting and population
This study was approved by the Institutional Review Board 
of the Durham Veterans Administration Medical Center 
(VAMC), Durham, NC, USA. A waiver for documentation 
of informed consent was approved to preserve participant 
anonymity. All procedures followed were in accordance 
with the ethical standards of the responsible committee 
on human experimentation (institutional and national) and 
with the Helsinki Declaration of 1975, as revised in 2000. 
Informed consent was obtained from all participants for being 
included in the study.
In 2012, a randomly selected subset of 1,999 veterans’ 
affairs (VA) patients from a larger claims-based cohort of 
7,933 veterans in the Durham VAMC catchment area with 
one or more of four cardiometabolic conditions (diabetes, 
hypertension, dyslipidemia, and heart failure) were sent a 
mailed survey. Veterans were initially selected in the larger 
claims-based cohort from an initial cohort of 29,368 veterans 
identified from Durham VAMC medical records. Veterans 
were excluded if they had no outpatient utilization in 2008 
(n=3,001), were receiving outpatient care at other VAMCs 
(n=11,594), died before the end of the study period (n=518), 
were younger than 40 years in 2008 (n=173), had a diagno-
sis for these conditions that could not be confirmed in VA 
claims data (n=5,363), were seen in outpatient primary care 
clinics staffed by resident physicians (n=339), had a medica-
tion for at least one of these four conditions that could not 
be confirmed in claims data (n=401), or were missing data 
for marital status or copayment status (n=46). We restricted 
the sample to veterans aged 40 years or older because the 
risk of cardiovascular disease increases markedly with each 
20 mmHg increment in systolic blood pressure for adults 
40 years and over28 and the onset for the majority of type 2 
diabetes patients occurs after the age of 40 years. By mailing 
a survey to a random 1,999 of these 7,933 patients, we were 
able to link the survey data for respondents back to their 
VAMC claims data to obtain information on demographic 
and clinical factors to include as covariates.
Measures
The survey included a validated two-domain self-reported 
measure of medication nonadherence that assesses extent 
of nonadherence and reasons for nonadherence.27 The 
three-item nonadherence extent measure asks respondents 
to complete the following statements using a 7-day recall 
period: “I took all doses of my [condition] medication”, 
“I missed or skipped at least one dose of my [condition] 
medication”, and “I was not able to take all of my [condi-
tion] medication”. The five response options measured 
frequency: never, rarely, sometimes, often, and always.29 
Participants who reported nonadherence on the extent scale 
were asked to complete the 21-item measure of reasons for 
nonadherence in the last 7 days separately for each condi-
tion for which they were taking medications (ie, hyperten-
sion, dyslipidemia, and type 2 diabetes) using five-point 
scales anchored by “not at all” and “very much”. Patients 
also completed the validated30–35 Mental Health Inventory 
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(MHI)-5 scale developed by Veit and Ware36 as a measure 
of depressive symptomology.
To examine and adjust for demographic differences 
between survey respondents across cardiometabolic condi-
tions and levels of depressive symptom burden, we con-
structed covariates for age (,65 years, 65+ years), sex, race 
(Caucasian, non-Caucasian, and unreported), marital status 
(married, divorced/widowed, single/never married, and 
unknown), copayment status (free VA care or not), number 
of cardiometabolic conditions (1, 2, 3, or 4), number of other 
chronic conditions,37 and number of VA prescribers (0, 1, 2, 
3, or 4+) in 2012 from information VA claims data.
Analysis
All analyses were conducted using Stata/MP (v12.1; Stata-
Corp LP, College Station, TX, USA). We did not analyze 
data for the congestive heart failure patients due to the small 
sample size. One of the three extent of nonadherence items 
(“I took all of my doses of [condition] medication”) was 
not highly correlated with the other two items (r=0.27 and 
r=0.20) as it had been in the initial validation study involv-
ing oral administration.27 In this self-administration of the 
measure, that item, which was designed to be reverse-scored 
to reduce acquiescence bias, produced substantial measure-
ment error, with many participants responding in a way that 
was inconsistent with the other two items. Thus, we excluded 
this item. The remaining two items were highly correlated 
(r=0.58) and had skewed distributions, with most respondents 
responding “never” (ie, perfect adherence). Accordingly, 
following our prior research, responses of “never” were 
coded as “adherent”, while all other responses were coded as 
“nonadherent”.27 Respondents were included in the analysis 
for nonadherence reasons if at least one extent question was 
coded as nonadherent. Reasons for nonadherence examined 
among those reporting nonadherence on the extent scale were 
treated as individual items and dichotomized, with responses 
of “not at all” coded as “no”, and all others as “yes”.27
We calculated a weighted MHI-5 score for respondents 
who responded to at least four out of five items by taking 
the mean of all items for which responses were provided. 
Scores were then scaled from 0 to 100. We assigned 
MHI-5 scores ,65 and $65 as “low” and “high” depressive 
symptom burden, respectively (based on validity testing of 
Rumpf et al33 against Diagnostic and Statistical Manual of 
Mental Disorders [DSM] IV criteria).
We first compared survey respondents and non-respondents 
on demographic variables available from the VA claims 
data (ie, age, sex, marital status, race, copayment status, 
number of cardiometabolic conditions, and number of VA 
prescribers in 2012). For each of the three cardiometabolic 
conditions, we then estimated logistic regression models 
to compare the odds of nonadherence (ie, anything other 
than “never” on the extent of nonadherence scale) between 
respondents with high and low depressive symptom burden 
adjusting for the previously mentioned demographic vari-
ables. Among participants reporting nonadherence in each 
of the three condition cohorts, we then estimated a logistic 
regression for each reason for nonadherence, controlling 
for the same covariates to understand whether the odds of 
endorsing a reason for nonadherence differed by depressive 
symptom burden. We corrected for multiple comparisons in 
the 63 regressions (21 reasons × 3 cohorts) using Benjamini 
and Hochberg’s approach to control for false discovery 
rate;38,39 a post-adjusted P-value of ,0.05 was considered 
significant.
Results
comparison of survey respondents and 
non-respondents
We received 1,026 returned surveys of the 1,999 originally 
mailed (response rate =51.3%). Respondents were more 
likely than non-respondents to be greater than 65 years of 
age, Caucasian, married, and required to pay VA copayments 
(Table 1). Many survey respondents completed two or all 
three self-reported medication adherence measures since they 
had two or more of the three conditions of interest: 415 (40%) 
completed the hypertension and cholesterol items on the sur-
vey; 24 (2%) completed the cholesterol and diabetes items; 
44 (4%) completed the hypertension and diabetes items; and 
358 (35%) completed items for all three conditions.
Prevalence of nonadherence and association 
with depressive symptoms
The unadjusted proportion of participants reporting non-
adherence was similar across the three conditions: 37% 
(n=338) of 917 participants taking antihypertensives, 37% 
(n=168) of 437 participants taking diabetes medications, 
and 39% (n=330) of 849 participants taking lipid-lowering 
medications (Table 2). The unadjusted difference between 
the depression symptom burden groups was only signifi-
cant among participants taking lipid-lowering medications 
(46% vs 34%, P=0.001). Adjusted analyses were consistent. 
That is, the odds of nonadherence to medications to manage 
dyslipidemia were significantly greater (odds ratio [OR]: 
1.42, P=0.025) among participants with depressive symptoms 
than those without (Table 3). In contrast, the adjusted odds 





Table 1 comparison of survey responders and non-responders
Completed survey P-value
Yes (n=1,026) No (n=974)
N % N %
Age in years (mean, sD) 70.0 9.7 69.0 10.7 0.036
Age (n, %)
.65 years 303 29.5 341 35.0 0.010
40–64 years 723 70.5 633 65.0
sex (n, %)
Male 969 94.4 934 95.9 0.145
Female 57 5.56 40 4.1
race (n, %)
White 687 67.0 569 58.4 ,0.001
Black 290 28.3 369 37.9
Other 21 2.1 22 2.3
Unknown 28 2.7 14 1.4
Marital status (n, %)
Married 679 66.2 570 58.5 0.001
Divorced/widowed 216 21.0 241 24.7
single/never married 95 9.3 101 10.4
Unknown 36 3.5 62 6.4
Pays health care copay (n, %)
Yes 287 28.0 227 23.3 0.019
no 739 72.0 746 76.6
Missing 0 0.0 1 0.1
Pays prescription copay (n, %)
Yes 711 69.3 605 62.1 0.001
no 315 30.7 368 37.8
Missing 0 0.0 1 0.1
gagne comorbidity score (median, iQr) 0.3 1.5 0.0 1.3 0.012
number of conditions (mean, sD) 6.39 5.0 6.50 5.0 0.613
number of VA prescribers (n, %)
0 52 5.1 63 6.5 0.025
1 628 61.2 540 55.4
2 232 23.6 226 23.2
3 70 6.8 80 8.2
4 44 4.3 64 6.7
Notes: P-values were estimated with two- sample t-test for age and number of conditions; with Wilcoxon rank sums for the gagne score; and with Fisher’s exact test for all others.
Abbreviations: iQr, interquartile range; sD, standard deviation; VA, veterans’ affairs.
of nonadherence did not differ by depressive symptoms for 
participants taking antihypertensives (OR: 1.24, P=0.15) or 
diabetes medications (OR: 1.15, P=0.51).
reasons for nonadherence and 
association with depressive symptoms
Among the subset reporting nonadherence, the most frequent 
reason for not taking medications for all three conditions 
was “I forgot” (Table 4), but the proportion endorsing this 
reason was only significantly different between depressed 
and non-depressed for nonadherence to lipid-lowering 
medications (53% vs 38%, P=0.01). For hypertension 
and dyslipidemia medications, the second most frequently 
endorsed reason was “I ran out of medication”, but this 
was only significantly associated with depressive symp-
toms in the dyslipidemia cohort. In both hypertension and 
dyslipidemia cohorts, there were significant differences by 
depressive symptoms in endorsement of “I was afraid they 
may affect my sexual performance”, “I was worried about 
taking them for the rest of my life”, “I was busy”, “They cost 
a lot of money”, “I had other medications to take”, “I was 
feeling too ill to take them”, “I was afraid the medication 
would interact with other medication I take”, “I was afraid 
of becoming dependent on them”, and “I was supposed to 
take them too many times a day”. In the diabetes cohort, 
there were no significant differences by depressive symp-
toms for any of the 21 reasons in unadjusted or adjusted 
analyses.
Adjusted results were generally similar to the bivariate 
associations (Table 5), although more reasons remained 
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Table 2 Unadjusted percent self-reported adherence and nonadherence by condition














Mhi .65 (yes) 59.9 40.1 0.059 54.1 45.9 0.001 58.6 41.4 0.102
Mhi ,65 (no) 65.2 34.8 65.6 34.4 64.9 35.1
Age (years)
40–64 59.2 40.8 0.034 54.3 45.7 0.001 58.2 41.8 0.092
65+ 65.3 34.5 65.3 34.7 65.0 35.0
sex
Male 63.8 36.2 0.068 61.4 38.6 0.264 63.9 36.1 0.009
Female 52.7 42.3 55.6 44.4 38.5 61.5
race
White 65.1 34.9 0.139 66.0 34.0 ,0.001 65.8 34.2 0.145
Black 58.2 41.8 51.2 48.3 56.2 43.8
Other 66.7 33.3 53.1 46.9 62.5 37.5
Marital
Married 63.9 36.1 0.390 64.5 35.6 0.013 64.7 35.3 0.389
Divorced/widowed 61.7 38.3 52.5 47.5 58.1 41.9
never married 58.8 41.2 55.8 44.2 56.9 43.1
Unknown 100 0.0 40.0 60.0 100.0 0.0
Pays health care copay
Yes 61.3 38.7 0.797 67.1 32.9 0.058 66.4 33.6 0.528
no 63.6 36.4 58.8 41.2 61.3 38.7
Unknown 66.7 36.9
Pays prescription copay
Yes 60.9 39.1 0.118 62.0 38.0 0.759 62.9 37.1 0.924
no 68.2 31.8 59.0 41.0 61.6 38.4
Unknown 66.7 33.3
number of conditions
1 85.7 14.3 0.458 0.792 0.879
2 62.2 37.8 62.4 37.6 65.8 34.2
3 64.2 35.8 60.1 39.9 61.6 38.4
4 55.6 44.4 58.8 41.2 60.7 39.3
number of VA prescribers
0 62.6 37.4 0.278 0.433 0.157
1 63.7 36.3 60.6 39.4 65.5 34.5
2 63.2 36.8 57.5 42.5 63.9 36.1
3 53.9 46.2 61.8 38.2 43.6 56.4
4 72.7 27.3 60.4 39.6 63.4 36.6
Note: Percentages and P-values estimated using Fisher’s exact test.
Abbreviations: Mhi, Mental health inventory; VA, veterans’ affairs.
statistically significant between groups with hypertensive 
medications than dyslipidemia (six reasons vs two reasons). 
The group differences by depression symptom burden dis-
appeared for the most frequently reported nonadherence 
reasons.
Discussion
This study represents the first comparison, to our knowledge, 
of the association between depressive symptoms and self-
reported medication nonadherence and reasons for nonadher-
ence across three concordant cardiometabolic conditions. We 
expected that the association between depressive symptoms 
and nonadherence and reasons for nonadherence might differ 
by condition because the individual medication regimens 
differ among these conditions in terms of regimen complex-
ity, side effects, out-of-pocket costs, and consequences of 
nonadherence.
Our rates of extent of nonadherence are similar to non-
adherence rates from prior condition-specific analyses based 
on medication refill data,1,20 but lower than nonadherence 
rates reported in studies using other self-report measures.12,40 
In our study, depressive symptom burden was significantly 





Table 3 Adjusted self-reported nonadherence by condition
Condition Hypertension   
n=917
Dyslipidemia   
n=849
Type 2 diabetes  
n=437
Covariate OR P-value OR P-value OR P-value
high depressive symptom burden 1.24 0.149 1.42 0.025 1.15 0.512
Age $65 years 0.77 0.087 0.74 0.058 0.84 0.450
Female 1.55 0.139 0.88 0.706 2.55 0.041
race
Black 1.38 0.045 1.59 0.005 1.39 0.139
Other 0.87 0.727 1.65 0.196 0.83 0.75
Marital status
Divorced/widowed 1.03 0.875 1.55 0.016 1.23 0.401
single/never married 1.03 0.265 1.21 0.325 1.01 0.969
Pays health care copay 1.19 0.347 0.94 0.723 0.98 0.938
Pays prescription copay 1.45 0.038 1.17 0.381 1.09 0.72
number of conditions
3 0.90 0.464 0.99 0.944 1.04 0.877
4 1.51 0.254 1.11 0.792 1.25 0.633
number of VA prescribers
1 0.88 0.523 1.34 0.199 0.82 0.496
2 0.87 0.562 1.40 0.187 0.73 0.355
3 1.33 0.341 1.05 0.338 1.81 0.162
4 0.63 0.199 1.16 0.683 0.83 0.674
Abbreviations: Or, odds ratio; VA, veterans’ affairs.
associated with extent of nonadherence to lipid-lowering 
medications but not to nonadherence to antihypertensive 
or diabetes medications. The finding of no association for 
antihypertensive or diabetes medications is at odds with 
other condition-specific studies, which have used differ-
ent adherence and depression measures (antihypertensive, 
diabetes).40,41–44 The lack of an observed difference in our 
study may be the result of measurement sensitivity (MPR 
and various self-report), or, in the case of diabetes, small 
sample size (168 diabetes vs 578 for hypertension and 518 
for dyslipidemia). Future research in larger samples should 
examine the extent of and reasons for nonadherence sepa-
rately for individuals taking oral agents and those taking 
insulin. We suspect there are important differences between 
oral and injectable diabetes medications, but our measure did 
not address these medication modes independently.
In addition to being novel by assessing medication 
nonadherence in concordant conditions using a consistent 
measure in the same population at the same time, this study 
is also novel because we examined whether the impact of 
depressive symptoms on reasons for nonadherence differed 
between these three conditions. We found that some rea-
sons offered for nonadherence varied between participants 
reporting higher and lower depression symptom burden. 
Although the overall top reason for nonadherent behavior 
in all conditions was forgetting, this reason was not sig-
nificantly different between depressed and  non-depressed 
respondents in any condition. Participants with greater 
depressive symptom burden taking antihypertensive 
medications expressed more concerns about the medication, 
although participants with a higher depressive symptom 
burden taking dyslipidemia medications were more likely 
to actually be nonadherent. Cost was also a concern for 
individuals with a higher depressive symptom burden taking 
hypertension and dyslipidemia medications, even though 
it was not one of the most commonly endorsed reasons for 
any condition. Although many veterans obtain VA medica-
tions at no cost or for a relatively low copayment (US$9 
per 30-day supply), participants with a higher depressive 
burden with these conditions were somewhat more likely 
to be responsible for copays.
These adjusted results suggest that extent of nonadher-
ence to lipid-lowering medications may have the greatest 
room for improvement for patients with comorbid depres-
sion. Providers may want to assess whether patients who are 
nonadherent to lipid-lowering medications are concerned 
about having to take them for their entire lives or out-of-
pocket costs because these two reasons were more likely 
to be endorsed by participants with depressive symptoms. 
Participants were also concerned about the impact of anti-
hypertensives on their sexual performance45 and complexity 
of their regimen, so these issues should be considered when 
counseling patients about increasing their adherence. Simi-
lar to Laba et al46 we assume that medication  nonadherence 
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is a multifactorial outcome influenced not only by the 
patient’s affective status, but also by symptom severity, 
complexity of the medication regimen, number and nuisance 
value of the medication side effects, short- and medium-
term consequences of not taking the medication, and the 
affordability of the drug to the patient. It is of particular 
interest that adherence was worst for dyslipidemia, which 
arguably has the least complex regimen and fewest side 
effects. Several reasons may explain this result: Elevated 
cholesterol is relatively asymptomatic; cholesterol levels 
do not vary significantly over short periods of time; and 
cholesterol levels cannot be self-monitored. In contrast, 
elevated blood pressure and blood glucose cause symptoms; 
values can vary significantly over short periods of time; and 
patients can self-monitor their blood pressure and blood 
glucose levels.
Table 4 Frequency and percent of reported reasons for nonadherence by depressive symptom burden and condition














Freq % Freq % Freq % Freq % Freq % Freq %
Negative expectations or worry
4 i worried about taking them  
for the rest of my life
22 12.64 38 29.92 ,0.001 15 9.87 36 26.47 ,0.001 7 8.97 18 26.87 0.070
10 i was afraid of becoming  
dependent on them
10 5.88 15 15.20 0.018 14 9.21 24 17.52  0.012 5 6.49 6 9.09 0.692
11 i was afraid they may affect  
my sexual performance
22 12.64 39 29.77 ,0.001 19 12.18 33 23.24 ,0.001 10 12.82 16 25.53 0.070
19 i was afraid the medication  
would interact with other  
medication i take
17 9.94 21 17.21 0.038 10 6.58 21 15.11  0.030 5 6.49 9 13.85 0.070
Poor memory
2 i forgot 78 43.33 70 51.85 0.095 59 37.82 76 52.78  0.011 41 5.62 31 41.89 0.787
18 i ran out of medication 44 25.73 41 31.78 0.117 31 20.0 39 27.66  0.044 22 28.21 16 24.24 0.436
Complex medication regimen
15 i was supposed to take them  
too many times a day
4 2.35 14 11.38 0.013 7 4.64 16 11.68  0.012 4 5.19 8 12.12 0.070
16 i had other medications to  
take
17 10.06 30 24.39 0.015 15 9.87 24 17.65  0.013 8 10.39 7 10.94 0.692
Concerns about drug effects
3 The medication caused some  
side effects
23 13.07 25 19.84 0.046 22 14.47 33 24.09  0.012 10 12.82 19 27.94 0.070
17 They make me need to  
urinate too often
30 17.34 35 28.23 ,0.001 20 13.16 28 20.44  0.012 12 15.38 13 19.70 0.184
20 My (lab measure) was too low 32 18.29 19 15.57 0.623 13 8.44 13 9.42  0.716 20 25.64 22 33.33 0.428
21 i was feeling too ill to take  
them
18 1.47 22 18.18 0.044 11 7.19 24 17.78  0.012 10 12.82 9 13.85 0.353
Does not take condition seriously
13 i felt i did not need them 24 14.20 20 16.53 0.407 18 11.92 23 16.55  0.081 10 12.99 13 19.70 0.184
7 i did not have any symptoms  
of (condition)
33 19.19 27 22.50 0.033 21 13.82 24 18.05  0.081 18 22.78 17 25.37 0.977
Financial burden
5 They cost a lot of money 27 15.61 32 25.20 ,0.001 14 9.40 25 18.25 ,0.001 10 12.82 11 16.18 0.153
Interferes with lifestyle
1 i was busy 26 14.86 33 25.78 0.015 21 13.82 26 18.71  0.025 14 18.18 13 19.12 0.692
6 i came home late 32 18.5 28 23.14 0.414 28 18.79 25 18.25  0.559 19 25.33 16 23.19 0.738
8 i was with friends or family  
members
31 17.92 26 21.49 0.117 20 13.25 24 17.52  0.116 13 16.88 9 13.24 0.911
9 i was in a public place 20 11.83 18 14.88 0.300 16 10.67 16 11.85  0.523 11 14.29 6 8.96 0.869
12 The time to take them was  
between my meals
18 10.47 18 14.52 0.06 17 11.04 18 12.86  0.287 7 8.97 15 22.39 0.070
14 i was traveling 40 22.99 26 2.63 0.843 32 21.05 23 16.91  0.716 27 34.62 13 19.40 0.911
Abbreviation: FDr-p, false discovery rate P-value; Freq, response frequency.





Table 5 Adjusted odds of self-reported reasons for nonadherence among participants with high depressive symptom burden




Type 2 diabetes  
(n=167)
No Item OR FDR-p OR FDR-p OR FDR-p
Negative expectations/worry
4 i worried about taking them for the  
rest of my life
3.09 0.011 3.63 0.021 4.96 0.105
10 i was afraid of becoming dependent on them 2.38 0.152 2.13 0.119 1.44 0.818
11 i was afraid they may affect my sexual  
performance
3.09 0.011 2.34 0.084 3.41 0.205
19 i was afraid the medication would interact  
with other medications i take
2.27 0.108 2.64 0.105 2.79 0.391
Poor memory
2 i forgot 1.44 0.263 1.71 0.116 0.70 0.53
18 i ran out of medication 1.54 0.252 1.61 0.206 0.94 0.979
complex medication regimen
15 i was supposed to take them too many times  
a day
6.52 0.017 2.40 0.185 3.38 0.348
16 i had other medications to take 3.11 0.011 1.70 0.282 0.98 0.979
Concerns about drug effects
3 The medication caused some side effects 1.42 0.479 2.03 0.116 2.88 0.205
17 They make me need to urinate too often 2.33 0.028 2.04 0.116 3.10 0.252
20 My (lab measure) was too low 1.07 0.854 1.36 0.573 1.57 0.488
21 i was feeling too ill to take them 1.57 0.386 2.76 0.084 1.16 0.922
Does not take condition seriously
13 i felt i did not need them 1.62 0.252 1.45 0.452 1.78 0.445
7 i did not have any symptoms of (condition) 1.26 0.613 1.38 0.503 2.54 0.348
Financial burden
5 They cost a lot of money 2.86 0.011 3.17 0.042 1.96 0.445
Interferes with lifestyle
1 i was busy 1.90 0.126 1.50 0.402 0.86 0.922
6 i came home late 1.22 0.613 0.91 0.85 0.53 0.445
8 i was with friends or family members 1.20 0.621 1.40 0.483 1.02 0.979
9 i was in a public place 1.31 0.613 1.00 0.999 0.64 0.652
12 The time to take them was between my meals 1.31 0.613 1.05 0.951 3.81 0.205
Abbreviations: FDr-p, false discovery rate P-value; Or, odds ratio.
There are several limitations to this study. First, these 
associations between reasons for nonadherence and depres-
sive symptom burden are cross-sectional, and they should not 
be considered causal relationships. We adjusted for a number 
of demographic and clinical variables in our analysis, but 
unobserved covariates (eg, severity of conditions, income, 
daily pill burden) may have influenced our findings. Second, 
it is possible that individuals with high vs low depressive 
burden have different reporting tendencies, such that self-
reported information may be more accurate among one group 
than the other (eg, Tang et al17; but also see Wang et al7 
 Gonzalez et al47). Third, we do not have information about 
what class(es) of medications our participants were taking for 
their conditions, which could influence extent of nonadher-
ence and specific reasons for nonadherence. Fourth, we did not 
have access to medication possession ratios from claims data 
 contemporaneous to this survey, which would have allowed us 
to compare how the association of depressive symptom bur-
den varies  between self-reported medication adherence and 
refill measures of adherence. Last, the estimated association 
between depressive symptoms and self-reported medication 
nonadherence may be subject to survey response bias, since 
survey responders were more likely to be older, white, and 
married than non-responders.
Conclusion
This research provides initial evidence demonstrating hetero-
geneity in both the extent of medication nonadherence and 
specific reasons for nonadherence among individuals with 
and without depressive symptoms in three concordant car-
diometabolic conditions. Survey respondents with depressive 
symptoms generally expressed more concerns about medica-
tion side effects/interactions and the duration and frequency 
of taking their medications than participants without depres-
sive symptoms. Our results suggest that clinicians may be 
able to identify specific medication concerns of participants 
with depressive symptoms that can serve as intervention 
targets for achieving improved adherence.




extent and reasons for nonadherence
Future research should systematically reckon with the 
variety of regimens, side effects, and costs of different 
medications within chronic conditions to observe which 
factors are medication-specific, which are associated with 
depressive symptom burden, and how these factors interact. 
With a framework to structure short- and medium-term costs 
and rewards for adherence, the heterogeneity in reasons for 
medication nonadherence across chronic conditions, medica-
tion classes, and patient characteristics may begin to form 
more predictable categories. Similarly, longitudinal studies 
of variability in reasons for nonadherence and how these 
reasons fluctuate with the point of pharmaceutical interven-
tion (ie, initiation vs maintenance) and changing depressive 
symptom burden over time are also needed.29 Together, these 
areas of research will inform development of more effective 
interventions to improve medication adherence in at-risk 
patient populations.
Disclosure
Dr Maciejewski has received consultation funds from 
Daiichi Sankyo and ResDAC at the University of 
Minnesota, and owns stock in Amgen due to his spouse’s 
employment. Dr Beadles, Dr Reeve, Dr Weidenbacher, 
and Dr Voils report that they have no conflicts of interest 
in this work.
References
1. Cramer JA. A systematic review of adherence with medications for 
diabetes. Diabetes Care. 2004;27(5):1218–1224.
2. Aikens JE, Piette JD. Longitudinal association between medication adher-
ence and glycaemic control in Type 2 diabetes. Diabet Med. 2013;30(3): 
338–344.
3. Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discon-
tinuation in high-risk patients: a systematic review of the evidence. Curr 
Pharm Des. 2011;17(33):3669–3689.
4. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence 
and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9): 
794–811.
5. Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve 
adherence to self-administered medications for chronic diseases in the 
United States: a systematic review. Ann Intern Med. 2012;157(11): 
785–795.
6. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for 
noncompliance with medical treatment: meta-analysis of the effects of 
anxiety and depression on patient adherence. Arch Intern Med. 2000; 
160(14):2101–2107.
7. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncom-
pliance with antihypertensive medications: the impact of depressive 
symptoms and psychosocial factors. J Gen Intern Med. 2002;17(7): 
504–511.
8. Wing RR, Phelan S, Tate D. The role of adherence in mediating the 
relationship between depression and health outcomes. J Psychosom Res. 
2002;53(4):877–881.
9. Gonzalez JS, Safren SA, Cagliero E, et al. Depression, self-care, and 
medication adherence in type 2 diabetes: relationships across the full 
range of symptom severity. Diabetes Care. 2007;30(9):2222–2227.
10. Cha E, Erlen JA, Kim KH, Sereika SM, Caruthers D. Mediating roles 
of medication-taking self-efficacy and depressive symptoms on self-
reported medication adherence in persons with HIV: a questionnaire 
survey. Int J Nurs Stud. 2008;45(8):1175–1184.
11. Schoenthaler A, Ogedegbe G, Allegrante JP. Self-efficacy mediates the 
relationship between depressive symptoms and medication adherence 
among hypertensive African Americans. Health Educ Behav. 2009; 
36(1):127–137.
12. Aggarwal B, Mosca L. Lifestyle and psychosocial risk factors predict 
non-adherence to medication. Ann Behav Med. 2010;40(2):228–233.
13. Krousel-Wood MA, Frohlich ED. Hypertension and depression: coex-
isting barriers to medication adherence. J Clin Hypertens (Greenwich). 
2010;12(7):481–486.
14. Gentil L, Vasiliadis HM, Préville M, Bossé C, Berbiche D. Association 
between depressive and anxiety disorders and adherence to antihyper-
tensive medication in community-living elderly adults. J Am Geriatr 
Soc. 2012;60(12):2297–2301.
15. Khdour MR, Hawwa AF, Kidney JC, Smyth BM, McElnay JC. Poten-
tial risk factors for medication non-adherence in patients with chronic 
obstructive pulmonary disease (COPD). Eur J Clin Pharmacol. 2012; 
68(10):1365–1373.
16. Dempe C, Jünger J, Hoppe S, et al. Association of anxious and depres-
sive symptoms with medication nonadherence in patients with stable 
coronary artery disease. J Psychosom Res. 2013;74(2):122–127.
17. Tang HY, Sayers SL, Weissinger G, Riegel B. The role of depression 
in medication adherence among heart failure patients. Clin Nurs Res. 
2014;23(3):231–244.
18. Kim J, Oshima TC. Effect of multiple testing adjustment in differential 
item functioning detection. Educ Psychol Meas. 2013;73(3):458–470.
19. Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in 
the Department of Veterans Affairs. Am J Med. 2007;120(1):26–32.
20. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug 
adherence rates among patients with seven different medical conditions. 
Pharmacotherapy. 2008;28(4):437–443.
21. Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient 
characteristics associated with medication adherence. Clin Med Res. 
2013;11(2):54–65.
22. Piette JD, Kerr EA. The impact of comorbid chronic conditions on 
diabetes care. Diabetes Care. 2006;29(3):725–731.
23. Yapko MD. Brief Therapy Approaches to Treating Anxiety and Depres-
sion. Philadelphia, PA: Brunner-Mazel; 1989.
24. Greene SM. The relationship between depression and hopelessness. 
Implications for current theories of depression. Br J Psychiatry. 1989; 
154:650–659.
25. Martz E, Livneh H. Do posttraumatic reactions predict future time 
perspective among people with insulin-dependent diabetes mellitus? 
Rehabil Couns Bull. 2007;50(2):87–98.
26. Allwood MA, Baetz C, DeMarco S, Bell DJ. Depressive symptoms, 
including lack of future orientation, as mediators in the relationship 
between adverse life events and delinquent behavior. J Child Adolesc 
Trauma. 2012;5(2):114–128.
27. Voils CI, Maciejewski ML, Hoyle RH, et al. Initial validation of a 
self-report measure of the extent of and reasons for medication nonad-
herence. Med Care. 2012;50(12):1013–1019.
28. Sacks FM, Obarzanek E, Windhauser MM, et al. Rationale and 
design of the Dietary Approaches to Stop Hypertension trial (DASH). 
A multicenter controlled-feeding study of dietary patterns to lower 
blood pressure. Ann Epidemiol. 1995;5(2):108–118.
29. Voils CI, King HA, Neelon B, et al. Characterizing weekly self-reported 
antihypertensive medication nonadherence across repeated occasions. 
Patient Prefer Adherence. 2014;8:643–650.
30. Berwick DM, Murphy JM, Goldman PA, Ware JE Jr, Barsky AJ, 
Weinstein MC. Performance of a five-item mental health screening 
test. Med Care. 1991;29(2):169–176.
31. McHorney CA, Ware JE Jr. Construction and validation of an alternate 
form general mental health scale for the Medical Outcomes Study 
Short-Form 36-Item Health Survey. Med Care. 1995;33(1):15–28.
Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal that focuses on the growing importance of patient 
 preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and their 
role in  developing new therapeutic modalities and compounds to optimize 
clinical  outcomes for existing disease states are major areas of interest for 
the  journal. This journal has been accepted for indexing on PubMed Central. 
The  manuscript management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit http://www.
dovepress.com/testimonials.php to read real quotes from published authors.






32. McCabe CJ, Thomas KJ, Brazier JE, Coleman P. Measuring the mental 
health status of a population: a comparison of the GHQ-12 and the 
SF-36 (MHI-5). Br J Psychiatry. 1996;169(4):516–521.
33. Rumpf HJ, Meyer C, Hapke U, John U. Screening for mental health: 
validity of the MHI-5 using DSM-IV Axis I psychiatric disorders as 
gold standard. Psychiatry Res. 2001;105(3):243–253.
34. Friedman B, Heisel M, Delavan R. Validity of the SF-36 five-item Mental 
Health Index for major depression in functionally impaired, community-
dwelling elderly patients. J Am Geriatr Soc. 2005;53(11):1978–1985.
35. Cuijpers P, Smits N, Donker T, ten Have M, de Graaf R. Screening for 
mood and anxiety disorders with the five-item, the three-item, and the two-
item Mental Health Inventory. Psychiatry Res. 2009;168(3):250–255.
36. Veit CT, Ware JE Jr. The structure of psychological distress and well-
being in general populations. J Consult Clin Psychol. 1983;51(5): 
730–742.
37. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined 
comorbidity score predicted mortality in elderly patients better than 
existing scores. J Clin Epidemiol. 2011;64(7):749–759.
38. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practi-
cal and powerful approach to multiple testing. J Royal Statist Soc B. 
1995;57(1):289–300.
39. Thissen D, Steinberg L, Kuang D. Quick and easy implementation of 
the Benjamini-Hochberg procedure for controlling the false positive 
rate in multiple comparisons. J Educ Behav Stat. 2002;27(1):77–83.
40. McAdam-Marx C, Bellows BK, Unni S, et al. Determinants of glycaemic 
control in a practice setting: the role of weight loss and treatment adher-
ence (The DELTA Study). J Clin Pract. 2014;68(11):1309–1317.
41. Sjosten N, Nabi H, Westerlund H, et al. Effect of depression onset on 
adherence to medication among hypertensive patients: a longitudinal 
modelling study. J Hypertension. 2013;31(7):1477–1484; discussion 
1484.
42. Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes 
treatment nonadherence: a meta-analysis. Diabetes Care. 2008; 
31(12):2398–2403.
43. Gonzalez JS, Safren SA, Delahanty LM, et al. Symptoms of depression 
prospectively predict poorer self-care in patients with Type 2 diabetes. 
Diabet Med. 2008;25(9):1102–1107.
44. McKellar JD, Humphreys K, Piette JD. Depression increases diabetes 
symptoms by complicating patients’ self-care adherence. Diabetes 
Educ. 2004;30(3):485–492.
45. Voils CI, Sandelowski M, Dahm P, et al. Selective adherence to antihy-
pertensive medications as a patient-driven means to preserving sexual 
potency. Patient Prefer Adherence. 2008;2:201–206.
46. Laba TL, Brien JA, Jan S. Understanding rational non-adherence to 
medications. A discrete choice experiment in a community sample in 
Australia. BMC Fam Pract. 2012;13:61.
47. Gonzalez JS, Schneider HE, Wexler DJ, et al. Validity of medication 
adherence self-reports in adults with type 2 diabetes. Diabetes Care. 
2013;36(4):831–837.
